a1 Immunisation, Hepatitis and Blood Safety Department, Health Protection Services Colindale, Health Protection Agency, London, UK
a2 Department of Medicine, Addenbrooke's Hospital, Cambridge, UK
a3 Statistics, Modelling and Bioinformatics Department, Health Protection Services Colindale, Health Protection Agency, London, UK
In a cohort of 272 treatment-naive individuals with chronic hepatitis C infection acquired on a known date who were enrolled in the UK HCV National Register, a progressive improvement in response to treatment was found with the evolution of antiviral therapies from 20% (25/122) for interferon monotherapy to 63% (55/88) for pegylated interferon+ribavirin therapy. Multivariable analysis results showed increasing age to be associated with poorer response to therapy [odds ratio (OR) 0·84, 95% confidence interval (CI) 0·72–0·99, P=0·03] whereas time since infection was not associated with response (OR 0·93, 95% CI 0·44–1·98, P=0·85). Other factors significantly associated with a positive response were non-type 1 genotype (P<0·0001) and combination therapies (P<0·0001). During the first two decades of chronic HCV infection, treatment at a younger age was found to be more influential in achieving a sustained viral response than treating earlier in the course of infection.
(Accepted October 26 2011)
(Online publication November 29 2011)
c1 Author for correspondence: Dr H. E. Harris, Clinical Scientist – Epidemiology. Immunisation, Hepatitis and Blood Safety Department, Health Protection Services Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, UK. (Email: email@example.com)
† The UK HCV National Register Collaborators (Appendix 1) and the UK HCV National Register Steering Group (Appendix 2) are available online.